Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 6, 2014, Pages 1366-1373

  Katsuta, Narimasa ^a   Ohnuma, Tohru ^a   Maeshima, Hitoshi ^a   Takebayashi, Yuto ^a   Higa, Motoyuki ^a   Takeda, Mayu ^a   Nakamura, Toru ^a   Nishimon, Shohei ^a   Sannohe, Takahiro ^a   Hotta, Yuri ^a   Hanzawa, Ryo ^a   Higashiyama, Ryoko ^a   Shibata, Nobuto ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

clinical course; pentosidine; pyridoxal; vitamin B6

Indexed keywords

BIOLOGICAL MARKER; CHLORPROMAZINE; NEUROLEPTIC AGENT; PENTOSIDINE; PYRIDOXAL; ARGININE; LYSINE;

ACUTE STAGE SCHIZOPHRENIA; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; JAPANESE (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; REMISSION; SCHIZOPHRENIA; ACUTE DISEASE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ARGININE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYSINE; MALE; MIDDLE AGED; PYRIDOXAL; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906935329     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt234     Document Type: Article

References (18)

1. Marchbanks RM, Ryan M, Day IN, Owen M, McGuffin P, Whatley SA. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr Res. 2003;65:33-38.
2. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684-97, 643.
3. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287-310.
4. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400-409.
5. Jaisson S, Gillery P. Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin Chem. 2010;56:1401-1412.
6. Arai M, Yuzawa H, Nohara I, et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry. 2010;67:589-597.
7. Miyashita M, Arai M, Kobori A, et al. Clinical features of schizophrenia with enhanced carbonyl stress. Schizophr Bull. September 23, 2013. doi:10.1093/schbul/sbt129.
8. Overall JE,Gorham DR. The Brief Psychiatry Rating Scale. Psychol Rep. 1962;10:799-812.
9. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1-37.
10. Hatano T, Ohnuma T, Sakai Y, et al. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP). Psychiatry Res. 2010;177:27-31.
11. Maeshima H, Ohnuma T, Sakai Y, et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1410-1418.
12. Ohnuma T, Sakai Y, Maeshima H, et al. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1905-1912.
13. Jinno M, Takeuchi M, Watanabe A, et al. Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology. Hum Reprod. 2011;26:604-610.
14. Sanaka T, Funaki T, Tanaka T, et al. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron. 2002;91:64-73.
15. Arai M, Koike S, Oshima N, et al. Idiopathic carbonyl stress in a drug-naive case of at-risk mental state. Psychiatry Clin Neurosci. 2011;65:606-607.
16. Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2002;63:54-58.
17. Toyosima M, Maekawa M, Toyota T, et al. Schizophrenia with the 22q11.2 deletion and additional genetic defects: case history. Br J Psychiatry. 2011;199:245-246.
18. Monnier VM, Sell DR, Saxena A, et al. Measurement of oxidative stress: Technology, biomarkers and applications. Glycoxidative and carbonyl stress in aging and age-related diseases. In: Cutler RG, Rodriguez H, eds. Critical Reviews of Oxidative Stress and Aging.Advances in Basic Science, Diagnostics and Intervention, Vol 2. Singapore: World Scientific; 2003:414-426.